Sculptra (formerly New Fill) for facial wasting--where to find information on the patient-assistance program.Sculptra[TM] (marketed in some countries as New Fill[TM]) was approved in August 2004 by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. "for restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. ." It was approved narrowly for this use because of the great need of many patients--but the FDA wants to see more data before allowing its wider use for cosmetic cosmetic /cos·met·ic/ (koz-met´ik) 1. pertaining to cosmesis. 2. a beautifying substance or preparation. cos·met·ic n. purposes, where the need is not as great. The product is expensive in the U.S. (about three times the price in Europe)--in addition to the cost of doctors' services, which can vary greatly. It is important to find a physician who is well trained or experienced in its use. Dermik Laboratories (owned by Sanofi-Aventis), the company now selling Sculptra in the U.S., is setting up a patient-assistance program that will provide free or reduced-cost drug to patients who meet certain income and other eligibility requirements. It does not pay the doctors' bill, however. The key issue will be to get Sculptra covered by regular health insurance, like other reconstructive re·con·struc·tive adj. 1. Relating to or characterized by reconstruction. 2. Serving to rebuild, restore, or correct the appearance and function of defective, damaged, or misshaped body structures or parts: medicine. Some companies are refusing to pay for it by claiming it is "cosmetic." But many patients cannot maintain their job or career without the treatment. Information about Sculptra--choosing a doctor, getting coverage through one's health insurance, or getting patient assistance if insurance is not available--is changing rapidly: * Currently (December 2004) the best information is on an email list run by well-known activist Nelson Vergel. You can read an archive of the messages even without subscribing, at http://health.groups.yahoo.com/group/pozhealth/ Also, you can subscribe by sending a blank email to PozHealth-subscribe@yahoogroups.com--and then following the instructions you will receive from Yahoo to confirm that you want the subscription. If you subscribe you may want to use the Digest Digest: see Corpus Juris Civilis. (1) A compilation of all the traffic on a news group or mailing list. Digests can be daily or weekly. (2) Any compilation or summary. option (to get no more than one email per day), as recently there were about 30 new messages a week on Sculptra alone. Note the medical necessity letter to help doctors in requesting reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. , at http://health.groups.yahoo.com/group/PozHealth/message/8047. * The official number for both doctors and patients to call for the Sculptra Access Program is 1-888-SCULPTRA (888-728-5787). Also see the official Web site, http://www.sculptra.com/. Note the patient information sheet, but also the physician information at http://www.sculptra.com/US/resources/SculptraPI.pdf You could also use a Google search Google is owned by Google, Inc. whose mission statement is to "organize the world's information and make it universally accessible and useful". The largest search engine on the web, Google receives several hundred million queries each day through its various services. , such as "Sculptra patient assistance" (without the quotes), or "Sculptra 2005" (also without the quotes) to locate recent articles. A background article by Bob Roehr in the Dallas Voice The Dallas Voice is a lesbian, gay, bisexual and transgender (LGBT) newspaper in the Dallas, Texas metropolitan area. The Voice is a member of the National Gay Newspaper Guild. External links
|
|
||||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion